{"id":35717,"date":"2025-10-10T00:00:05","date_gmt":"2025-10-09T17:00:05","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=35717"},"modified":"2025-10-10T00:00:05","modified_gmt":"2025-10-09T17:00:05","slug":"lifespan-backed-algen-biotechnologies-partners-with-astrazeneca-to-advance-ai-drug-discovery","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=35717","title":{"rendered":"Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

NORWALK, Conn.<\/span><\/span>, Oct. 9, 2025<\/span><\/span> \/PRNewswire\/ — Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology.<\/p>\n

The partnership will combine Algen’s cutting-edge functional genomics and machine learning platform with AstraZeneca’s deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of next-generation medicines.<\/p>\n

Harry Robb<\/span>, Principal at Lifespan Vision Ventures, said “We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. This collaboration with AstraZeneca underscores the strength of Algen’s technology and its potential to transform drug discovery.”<\/p>\n

As an early investor, Lifespan Vision Ventures is proud to support Algen Biotechnologies in its mission to advance transformative therapies that improve patient outcomes in age-related diseases and extend healthspan.<\/p>\n

About Algen Biotechnologies<\/b><\/p>\n

Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang<\/span> and Christine Du<\/span> as a spin-out from Nobel laureate Jennifer Doudna’s<\/span> lab at UC Berkeley, Algen combines deep learning with high-throughput functional genomics to identify novel therapeutic targets. Its proprietary, end-to-end platform AlgenBrain\u2122 integrates advanced computational models with scalable, single-cell experimental systems to decode causal disease biology and accelerate the development of next-generation therapies. Algen is headquartered in San Francisco, CA.<\/span><\/p>\n

For more information, visit\u00a0www.algenbio.com<\/a>.<\/p>\n

About Lifespan Vision Ventures<\/b><\/p>\n

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human vitality.<\/p>\n

Contact: info@lifespanvision.com<\/a><\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

NORWALK, Conn.<\/span><\/span>, Oct. 9, 2025<\/span><\/span> \/PRNewswire\/ — Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology.<\/p>\n

The partnership will combine Algen’s cutting-edge functional genomics and machine learning platform with AstraZeneca’s deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of next-generation medicines.<\/p>\n

Harry Robb<\/span>, Principal at Lifespan Vision Ventures, said “We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. This collaboration with AstraZeneca underscores the strength of Algen’s technology and its potential to transform drug discovery.”<\/p>\n

As an early investor, Lifespan Vision Ventures is proud to support Algen Biotechnologies in its mission to advance transformative therapies that improve patient outcomes in age-related diseases and extend healthspan.<\/p>\n

About Algen Biotechnologies<\/b><\/p>\n

Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang<\/span> and Christine Du<\/span> as a spin-out from Nobel laureate Jennifer Doudna’s<\/span> lab at UC Berkeley, Algen combines deep learning with high-throughput functional genomics to identify novel therapeutic targets. Its proprietary, end-to-end platform AlgenBrain\u2122 integrates advanced computational models with scalable, single-cell experimental systems to decode causal disease biology and accelerate the development of next-generation therapies. Algen is headquartered in San Francisco, CA.<\/span><\/p>\n

For more information, visit\u00a0www.algenbio.com<\/a>.<\/p>\n

About Lifespan Vision Ventures<\/b><\/p>\n

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human vitality.<\/p>\n

Contact: info@lifespanvision.com<\/a><\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-35717","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35717"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35717\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}